Kerala HC allows Covishield second jab after 28 days in pvt sector

In a crucial intervention, the Kerala High Court on Monday ruled that the second dose of Covishield can be taken 28 days of taking the first dose in the private sector

Covishield, Covid-19 vaccine
IANS Kochi
2 min read Last Updated : Sep 06 2021 | 8:52 PM IST

In a crucial intervention, the Kerala High Court on Monday ruled that the second dose of Covishield can be taken 28 days of taking the first dose in the private sector, but this time frame will not be applicable to the free supply of vaccines.

The court noted that there have been exemptions given to the current 84 day period between the two doses to those officials who go for meetings and to students who are studying abroad, and thus, it is not fair to delay it as the vaccines have been already purchased by companies.

The Kitex group of companies had, in its petition filed last month, told the court that they have purchased the vaccine doses to be administered to its employees.

After giving the first dose, according to the Centre, the second dose could be given only after 84 days, which was contested by Kitex, which pointed out that since they have already purchased the vaccines and if the administration is going to be delayed, then the vaccines could get spoiled and would have to be thrown away.

On Monday, the Centre strongly opposed this, but the court overruled their objections, pointing out that while already there have been exemptions given to officials and students, it is not fair to delay the second dose to the employees and it can be given.

It, however, pointed out this 28 day period will not be available in the free supply quota of the government.

In its previous hearing, the court had asked the Centre to explain why is there a gap of 84 days to take the second dose of Covishield vaccine.

It also asked if it was possible to reduce the time gap if vaccines are sourced by parties themselves, and also asked the Centre whether the time gap was extended because it would lead to better efficacy or was it because of the problems in sourcing vaccines in time.

--IANS

sg/vd

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Kerala High CourtCoronavirus VaccineVaccinationSerum Institute of India

First Published: Sep 06 2021 | 8:52 PM IST

Next Story